Lorien Moore is Vice President, Corporate Development and Business Operations at Vesigen Therapeutics. Lorien has experienced all stages of pharmaceutical development, from pre-clinical through to commercialization, including international expansion.
Prior to joining Vesigen, Lorien was VP, Program Management and New Product Planning at Yumanity Therapeutics, where she was instrumental in the asset sale to Janssen and reverse merger with Kineta. She was also interim head of Business Development, Clinical Operations and CMC. Lorien has previously worked in corporate development, program management, new product planning, strategy, and in various commercial roles at Constellation, Flexion, Seres, Merck and Cubist. A number of her roles have involved company and asset acquisitions, integrations, and collaborations.
Prior to her experience in the pharmaceutical industry, Lorien spent 10 years working in consumer products companies (Ford, Gillette and P&G), with roles in finance, marketing, and sales. Lorien holds a B.A. from the University of Illinois and an MBA from the MIT Sloan School of Management.